Accessibility Menu
Traws Pharma logo

Traws Pharma(NASDAQ) TRAW

Current Price$0.62
Market Cap$9.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-100%
5 Year-100%
1 Year-62%
1 Month-28%
Traws Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.612026-07-20
Traws Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.83%USD 0.682026-07-13
1 month-28.18%USD 0.852026-06-18
3 month-52.29%USD 1.282026-04-21
Year to date-45.96%USD 1.132025-12-31
1 year-61.83%USD 1.602025-07-18
3 year-97.67%USD 26.252023-07-21
5 year-99.57%USD 140.752021-07-21
Since inception-100%USD 1,118,248.602013-07-25

Traws Pharma Financials at a Glance

Market Cap

$9.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.79M

Net Income (TTM)

-$23.94M

EPS (TTM)

-$2.27

P/E Ratio

-0.27

Dividend

$0.00

Beta (Volatility)

1.07 (Average)

Price

$0.62

Volume

30,307.449

Open

$0.62

Previous Close

$0.61

Daily Range

$0.61 - $0.63

52-Week Range

$0.60 - $3.27

Estimated Earnings Date

Aug 13, 2026

TRAW News

Foolcom-Featured.png

Traws Pharma Posts Q2 Revenue Jump

Motley Fool Markets TeamAug 14, 2025
Growth - GettyImages-905948482

Why Onconova Therapeutics Stock Soared Today

Joe TenebrusoFeb 17, 2021

This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!

Sean WilliamsFeb 22, 2014

3 Horrendous Health-Care Stocks This Week

Keith SpeightsFeb 22, 2014

Why Onconova Therapeutics Inc. Shares Imploded

Sean WilliamsFeb 20, 2014

Why Jabil Circuit, Inc., Onconova Therapeutics Inc., and Gogo Inc. Plunged Today

Dan CaplingerDec 18, 2013

Why Onconova Therapeutics Inc. Shares Crashed

Sean WilliamsDec 18, 2013

Keep an Eye on Onconova, Enzymotec, DepoMed, and Omeros Today

Leo SunDec 18, 2013

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Traws Pharma

Corgi ONTO 2x Daily ETF aims to deliver twice the daily performance of Onto Innovation Inc. by investing primarily in financial instruments that provide leveraged exposure. This fund is designed for investors seeking amplified returns based on the underlying security's performance.

Products and Services
  • Leveraged exposure to Onto Innovation Inc.
  • Daily investment results targeting 2x performance
  • Focus on asset management strategies
Growth Outlook
  • Market capitalization stands at approximately $1.08 million
  • Price range over the past year: $16.90 to $43.14
  • Potential for growth as market conditions evolve
Financial Highlights
  • Recent trading volume averages around 22,183 shares
  • Current price is $21.56, reflecting recent market adjustments
  • Trailing twelve months show a negative P/E ratio of -0.07
Corgi ONTO 2x Daily ETF operates within the asset management industry, focusing on providing investors with leveraged exposure to Onto Innovation Inc. The fund's strategy is particularly appealing for those looking to capitalize on short-term market movements. The recent price fluctuations indicate a dynamic market environment, which may present opportunities for growth. The fund's current market capitalization and trading volume suggest a level of investor interest, while the negative P/E ratio highlights the challenges faced in the current financial landscape. Overall, Corgi ONTO 2x Daily ETF represents a unique investment vehicle for those interested in leveraged strategies within the financial services sector.
AI Generated • Jul 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

7

CEO

Iain David Dukes, PhD

Website

www.trawspharma.com

Headquarters

Newtown, PA 18940, US

TRAW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

489.90%

Return on Capital

N/A

Return on Assets

-178.40%

Earnings Yield

-3.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.23M

Volume

30.31K

Avg. Volume

2.34M

Financials (TTM)

Gross Profit

$2.79M

Operating Income

-$24.10M

EBITDA

-$23.95M

Operating Cash Flow

-$15.35M

Capital Expenditure

$0.00

Free Cash Flow

-$15.35M

Cash & ST Invst.

$3.13M

Total Debt

$0.00

Traws Pharma Performance Analysis

Traws Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 226,0000.0%
20232023-12-31USD 226,0000.0%
20242024-12-31USD 226,0000.0%
20252025-12-31USD 2,790,0001134.5%
Traws Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-311.8%
Q22025-06-304694.7%
Q42025-12-31-100.0%
Q22026-03-31N/A
Traws Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -22.68-5.5%
20232023-12-31USD -22.57-0.5%
20242024-12-31USD -106.70372.8%
20252025-12-31USD 1.09N/A
Traws Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-48.8%
Q22025-06-3098.8%
Q42025-12-31-209.1%
Q22026-03-31-55.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$9.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.33M

N/A

Employees

7

N/A

Net Income

-$7.11M

-42.6%

EBITDA

-$6.90M

-32.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.13M

-81.4%

Total Debt

$0.00

N/A

Accounts Receivable

$1.69M

+9272.2%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.78%

N/A

Return on Invested Capital

2.83%

N/A

Free Cash Flow

-$2.58M

+73.9%

Operating Cash Flow

-$2.58M

+73.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COCPCocrystal Pharma, Inc.
$0.94+1.34%
BOLTBolt Biotherapeutics, Inc.
$4.29-4.13%
IMRNImmuron Limited
$1.15+1.42%
MBIOMustang Bio, Inc.
$0.62-5.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
VIVKVivakor
$5.49+2.17%
UTZUtz Brands
$14.12+0.89%
AALAmerican Airlines Group
$15.28+0.01%
SOFISoFi Technologies
$17.44+0.02%

Questions About TRAW

What is the current price of Traws Pharma?

Traws Pharma is trading at $0.62 per share.

What is the 52-week range for Traws Pharma?

Over the past 52 weeks, Traws Pharma has traded between $0.60 and $3.27.

How much debt does Traws Pharma have?

As of the most recent reporting period, Traws Pharma reported total debt of $0.00.

How much cash does Traws Pharma have on hand?

Traws Pharma reported $3.13M in cash and cash equivalents in its most recent financial results.

What is Traws Pharma’s dividend yield?

Traws Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services